magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 219180 Total View: 2502820
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Article Open Access http://dx.doi.org/10.26855/ijcemr.2020.10.002

Icariin Reverses the Elevated Expression of the Hepatic Transporters Oatp1a1, Oatp1a4, Oatp1a5, Oatp1b2 and Mrp2 in Spontaneously Hypertensive Rats

Yun Yue, Fanqun Zeng, Shu Fu, Yuting Wu, Yeli Li, Danli Yang *

Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou 563000, China.

*Corresponding author: Danli Yang

Published: August 3,2020

Abstract

The hepatic transporters organic anion transporting polypeptides (Oatps/OATPs) and multidrug resistance-associated proteins (Mrps) transport endogenous or exogenous substances such as bile acids. The aforementioned transporters also regulate blood pressure. Oatps/OATPs and Mrps were aber-rantly expressed in spontaneously hypertensive rats (SHRs). Icariin (ICA), one of the main active components of Herba Epimedii, delays hypertensive heart disease in SHRs. However, researchers have not yet determined whether ICA affects the aforementioned liver transporters in SHRs. The present study was designed to investigate the effects of icariin on the hepatic expressions of OATPs and Mrp2 in SHRs. The main methods used were real-time PCR and Western blot analysis. The results showed that ICA significantly reduced the abnormally elevated levels of the Oatp1a1, Oatp1a4, Oatp1a5, Oatp1b2, and Mrp2 mRNAs and/or proteins in the livers of SHRs. In conclusion, ICA re-verses the elevated expression of the hepatic transporters Oatp1a1, Oatp1a4, Oatp1a5, Oatp1b2 and Mrp2 in SHRs.

References

[1] Klaassen CD, Aleksunes LM. (2010). Pharmacological Reviews. 62: 1-96.

[2] Obaidat A, Roth M, Hagenbuch B. (2012). Annu Rev Pharmacol Toxicol. 52: 135-151. 

[3] Zhang Y, Csanaky IL, Selwyn FP, Lehman-McKeeman LD, Klaassen CD. (2013). Biochemical Pharmacology. 86: 437-445.

[4] Bühler H, Perschel FH, Fitzner R, Hierholzer K. (1994). Steroids. 59: 131-135. 

[5] Morris DJ, Souness GW. (1996). Endocrine Research Communications. 22: 793-801. 

[6] Hagenbuch B, Meier PJ. (2003). Biochim Biophys Acta. 1609: 1-18.

[7] Meier PJ, Stieger B. (2002). Annual Review of Physiology. 64: 635-661.

[8] Abe M, Toyohara T, Ishii A, Suzuki T, Noguchi N, Akiyama Y, Shiwaku HO, Nakagomi-Hagihara R, Zheng G, Shibata E, Souma T, Shindo T, Shima H, Takeuchi Y, Mishima E, Tanemoto M, Terasaki T, Onogawa T, Unno M, Ito S, Takasawa S, Abe T. (2010). Drug Metabolism & Pharmacokinetics. 25: 274-282.

[9] Sun P, Wang C, Liu Q, Meng Q, Zhang A, Huo X, Sun H, Liu K. (2014). Pharmacological Reports Pr. 66: 311-319.

[10] Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS. (2016). Journal of Clinical Pharmacology. 56: S205-S221. 

[11] Svoboda DS, Kawaja MD. (2012). Journal of Proteomics. 75: 1752-1763.

[12] Yue Y, Wu YT, Fu S, Qian ZQ, Li YL, Yang DL. (2017). Acta Academiae Medicinae Zunyi. 40: 469-474.

[13] Kang HK, Choi YH, Kwon H, Lee SB, Kim DH, Sung CK, Park YI, Dong MS. (2012). Food & Chemical Toxicology. 50: 2751-2759.

[14] Kapoor S. (2013). Chin Med J (Engl). 126: 400-404.

[15] Qian ZQ, Wang YW, Li YL, Zhu L, Wang JY, Yang DL. (2015). Journal of Zunyi Medical University. 38: 450-453.

[16] Wu YT, Qian ZQ, Fu S, Yue Y, Li YL, Sun RM, Huang B, Yang DL. (2017). European Journal of Pharmacology. 33: 1744-1749.

[17] Qian ZQ, Wang YW, Li YL, Li YQ, Ling Z, Yang DL. (2017). Biomedicine & Pharmacotherapy. 88: 823-831.

[18] Xu S, Yu J, Zhan J, Yang L, Guo L, Xu Y. (2017). Biomed Res Int. 2017: 1-17.

[19] Li Z, Cheung F S, Zheng J, Chan T, Zhu L, Zhou F. (2014). J Biochem Mol Toxicol. 28: 91-97.

[20]  Wu LX, Guo CX, Qu Q, Yu J, Chen WQ, Wang G, Fan L, Li Q, Zhang W, Zhou HH. (2012). Xenobiotica. 42: 339-348.

[21]  Song YH, Cai H, Gu N, Qian CF, Cao SP, Zhao ZM. (2011). Journal of Pharmacy & Pharmacology. 63: 541-549.

[22] Li Y, Jiang J, He Y, Jiang R, Liu J, Fan Z, Cheng Y. (2014). Journal of Sexual Medicine. 11: 2143-2152.

[23]  Zhu QN, Hou WY, Xu SF, Lu YF, Liu J. (2017). Life Sciences. 170: 108-114.

[24]  Guo Y, Jiang L. (2009). Journal of the Fourth Military Medical University. 30: 1700-1702.

[25]  Li N, Hartley DP, Cherrington NJ, Klaassen CD. (2002). Journal of Pharmacology & Experimental Therapeutics. 301: 551-560.

[26]  Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA. (2000). Am J Physiol Gastrointest Liver Physiol. 279: G1188-G1200.

[27] Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B. (2001). Pflugers Arch. 443: 188-195.

[28]  Fahrmayr C, Fromm M F, Konig J. (2010). Drug Metab Rev. 42: 380-401.

[29]  Csanaky IL, Lu H, Zhang Y, Ogura K, Choudhuri S, Klaassen CD. (2011). Hepatology. 53: 272-281.

[30]  Anne TN, Dietrich K. (2007). European Journal of Physiology. 453: 643-659.

[31] Devgun MS, El-Nujumi AM, O'Dowd GJ, Barbu V, Poupon R. (2012). Annals of Clinical Biochemistry. 49: 609-612.

[32]  Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop CE, Kumer SC, Unadkat JD. (2016). Drug Metabolism & Disposition the Biological Fate of Chemicals. 44: 1752-1758.

[33]  Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, Stern JO, Nehmiz G, Böcher WO, Asselah T, Tweedie D. (2014). Journal of Pharmacology & Experimental Therapeutics. 351: 403-412.

[34]  Gu X, Manautou JE. (2010). Drug Metabolism Reviews. 42: 482-538.

[35]  Dzierlenga AL, Clarke JD, Klein DM, Anumol T, Snyder SA, Li H, Cherrington NJ. (2016). Journal of Pharmacology & Expe-rimental Therapeutics. 358: 246-253.

[36]  Namisaki T, Schaeffeler E, Fukui H, Yoshiji H, Nakajima Y, Fritz P, Schwab M, Nies AT. (2014). Drug Metabolism & Dispo-sition the Biological Fate of Chemicals. 42: 2033-2040.

[37] Zhu QN, Zhang D, Jin T, Wu Q, Liu J, Lu YF. (2013). J Ethnopharmacol. 147: 215-219.

[38]  Qu XY, Tao LN, Zhang SX, Sun JM, Niu JQ, Ding YH, Song YQ. (2017). Environmental Toxicology & Pharmacology. 51: 16-22.


How to cite this paper

Icariin Reverses the Elevated Expression of the Hepatic Transporters Oatp1a1, Oatp1a4, Oatp1a5, Oatp1b2 and Mrp2 in Spontaneously Hypertensive Rats

How to cite this paper: Yun Yue, Fanqun Zeng, Shu Fu, Yuting Wu, Yeli Li, Danli Yang. (2020) Icariin Reverses the Elevated Expression of the Hepatic Transporters Oatp1a1, Oatp1a4, Oatp1a5, Oatp1b2 and Mrp2 in Spontaneously Hypertensive Rats. International Journal of Clinical and Experimental Medicine Research, 4(4), 117-125.

DOI: http://dx.doi.org/10.26855/ijcemr.2020.10.002